TD Cowen analyst Yaron Werber has maintained their bullish stance on CLDX stock, giving a Buy rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Yaron Werber has given his Buy rating due to a combination of factors, primarily the rapid and ahead‑of‑plan clinical execution for barzolvolimab across multiple indications. The Phase 3 chronic spontaneous urticaria studies finished enrollment six months earlier than expected, with additional pivotal work in inducible urticaria underway and well timed catalysts in prurigo nodularis and atopic dermatitis slated for 2026, supported by a cash position that should fund operations into 2027.
He also sees barzolvolimab as having potentially best‑in‑class efficacy based on Phase 2 outcomes in urticaria, where patients achieved strong and durable symptom control with a favorable safety profile and meaningful quality‑of‑life gains. Early data for the CDX‑622 bispecific add an additional source of upside, and together these advancing programs, derisked timelines, and multiple readouts in 2026 create an attractive risk‑reward setup that, in his view, justifies maintaining a Buy recommendation.
Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Amgen, and Ionis Pharmaceuticals. According to TipRanks, Werber has an average return of 23.6% and a 60.08% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $61.00 price target.